期刊文献+

依折麦布联合吉非罗齐治疗高脂血症的临床疗效和安全性分析 被引量:2

Safety and efficacy of ezetimibe combined with gemfibrozil in the treatment of hyperlipidemia
下载PDF
导出
摘要 目的探讨依折麦布联合吉非罗齐治疗高脂血症的安全性和有效性。方法选择2014年3月至2016年3月在我院接受治疗的高脂血症患者128例,以随机数字表法将其分为观察组和对照组,每组64例。对照组给予吉非罗齐治疗,观察组采用依折麦布联合吉非罗齐治疗,疗程为1个月。观察两组患者治疗前后总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白-胆固醇(HDL-C)以及低密度脂蛋白-胆固醇(LDL-C)等水平的变化。结果观察组总有效率为93.75%(60/64),明显高于对照组的76.56%(49/64)(P<0.05)。治疗后两组TC、TG和LDL-C均较治疗前显著降低,HDL-C显著升高,但观察组变化更显著,两组比较差异均有统计学意义(P<0.05)。观察组治疗后不良反应发生率为9.38%,对照组为15.63%,两组比较差异无统计学意义(P>0.05)。结论依折麦布联合吉非罗齐能在短时间内有效治疗高脂血症,降脂疗效明显优于单用吉非罗齐,且能同时降低TG和TC,安全性高。 Objective To explore the safety and efficacy of ezetimibe combined with gemfibrozil in the treatment of hyperlipidemia.Methods Totally 128 cases of hyperlipidemia patients treated in our hospital from March2014 to March 2016 were selected and divided into observation group and control group,with 64 cases in each group by the table of random number.Patients in control group only used gemfibrozil for treatment,and patients in observation group were treated with ezetimibe and gemfibrozil,the course of treatment being 1 month.Before and after treatment,the indexes of total cholesterol(TC),triglyceride(TG).high density lipoprotein cholesterol(HDL-C) and low density lipoprotein cholesterol(LDL-C) of the two groups were observed and compared.Results The total effective rate of observation group was higher than that of control group(93.75%vs.76.56%,P〈0.05).After treatment,TC,TG and LDL-C were decreased and HDL-C was increased significantly in the two groups,and the changes in observation group were more significant than control group.there being significant difference between the two groups(P〈0.05).After treatment,the adverse reaction rate of observation group and control group was 15.63%and 9.38%.there being significant difference between the two groups(P〈0.05).Conclusion Ezetimibe combined with gemfibrozil is effective in the treatment of hyperlipidemia in a short period of time with high safety,the lipid-lowering effect is better than the single use of gemifibrozil,and it can also reduce TG and TC.
作者 董佳敏 蔡薇
出处 《实用药物与临床》 CAS 2016年第11期1357-1359,共3页 Practical Pharmacy and Clinical Remedies
基金 江苏省苏州市科技计划项目申报书(应用基础研究计划-医疗卫生部分)
关键词 依折麦布 吉非罗齐 高脂血症 安全性 有效性 Ezetimibe Gemfibrozil Hyperlipidemia Safety Efficacy
  • 相关文献

参考文献10

二级参考文献108

  • 1高海青.第二次中国临床血脂控制状况多中心协作暨REALITY研究[J].华夏医药,2007,2(2):117-124. 被引量:16
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5222
  • 3The Collaborative Research Group for the Second Multi-center Survey of Clinical Management of Dyslipidemia in China.第二次中国临床血脂控制达标率及影响因素多中心协作研究[J].中华心血管病杂志,2007,35(5):420-427. 被引量:127
  • 4李中东,焦正,王宏图.胆固醇吸收抑制剂——依折麦布[J].中国药学杂志,2007,42(10):797-798. 被引量:9
  • 5《中国成人血脂异常防治指南》制定委员会.中国成人血脂异常防治指南[M].北京:人民卫生出版社,2007:7-9.
  • 6方圻,王钟林,宁田海,邵耕,陈在嘉,陆宗良,李健斋,林传骧,周北凡,诸骏仁,诸永康,陶萍,陶寿淇,龚兰生,顾复生,游凯,戴玉华.血脂异常防治建议[J].中华心血管病杂志,1997,25(3):169-175. 被引量:3067
  • 7Suchy D,Labuzek K,Stadnicki A,et al.Ezetimibe--a new ap-proach in hypercholesterolemia management[J].Pharmacol Rep,2011,63(6):1335-1348.
  • 8Cannon CP,Giugliano RP,Blazing MA,et al.Rationale and designof IMPROVE-IT(IMProved Reduction of Outcomes:Vytorin EfficacyInternational Trial):comparison of ezetimbe/simvastatin versus sim-vastatin monotherapy on cardiovascular outcomes in patients with acutecoronary syndromes[J].Am Heart J,2008,156(5):826-832.
  • 9Califf RM,Harrington RA,Blazing MA.Premature release of data fromclinical trials of ezetimibe[J].N Engl J Med,2009,361(7):712-717.
  • 10Sasaki J,Otonari T,Sawayama Y,et al.Double-dose pravastatinversus add-on ezetimibe with low-dose pravastatin-effects on LDLcholesterol,cholesterol absorption,and cholesterol synthesis inJapanese patients with hypercholesterolemia(PEAS study)[J].JAtheroscler Thromb,2012,19(5):485-493.

共引文献99

同被引文献13

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部